Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomitapide in Homozygous Familial Hypercholesterolemia
NCT01556906Phase 2Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Jun 2003
- Primary completion
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Aegerion Pharmaceuticals. Primary endpoint: Low-Density Lipoprotein Cholesterol at 16 weeks. Started Jun 2003; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT01556906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556906.